MADRID, Nov 27 (Reuters) - Canadian fund Brookfield

said on Wednesday it has dropped its plan to take over

Spain's Grifols due to a disagreement over the

pharmaceutical company's value.

Brookfield had filed a non-binding offer on Nov. 19 for

Grifols that valued the developer of human plasma-based drugs at

6.45 billion euros ($6.79 billion).

Grifols shares were down 6.9% at 1405 GMT after falling more

than 12% in earlier trading after Bloomberg first reported

Brookfield's decision, while the blue-chip IBEX 35 index was

down 0.7%.

"This morning Brookfield informed the Grifols Transaction

Committee that in the current circumstances it is not in a

position to continue with a potential offer for Grifols," the

Canadian company said in statement.

Brookfield had said in September it was interested in

launching a takeover bid jointly with the Grifols family,

pending successful completion of due diligence.

A spokesman for Grifols' founding family confirmed

Brookfield's exit.

"Brookfield is withdrawing its offer due to a discrepancy

over the price. The company has a much higher value (than what

Brookfield offered)," the spokesperson said, adding: "We

continue as we were."

It was unclear whether the family and Brookfield might

resume talks later on.

Company spokespeople for Grifols did not respond to requests

for comment.

($1 = 0.9505 euro)